Close
New

Medscape is available in 5 Language Editions – Choose your Edition here.

 

Pancreatic Necrosis and Pancreatic Abscess

  • Author: Abraham Mathew, MD, MS; Chief Editor: BS Anand, MD  more...
 
Updated: Apr 01, 2015
 

Background

Fluid and necrotic collections can occur as complications of acute pancreatitis. According to the latest classification, these can be divided into acute or delayed, depending on whether such a collection is of less than or more than 4 weeks' duration.[1]

In the acute period, the fluid collection is not well defined and is simply described as acute peripancreatic fluid collection. It is often associated with tissue edema. After 4 weeks, the fluid collection is much more organized with a definite wall and is described as a pseudocyt. A pseudocyst is a peripancreatic fluid collection containing high concentrations of pancreatic enzymes within a defined fibrous wall and lacking an epithelial lining. When a pseudocyst gets infected, it is called a pancreatic abscess.

Similarly, pancreatic necrosis can be an acute necrotic collection in which there is a variable amount of fluid and necrosis. By around 4 weeks, a walled-off pancreatic necrosis (WOPN) may form, in which the collection is defined by a fibrotic and inflammatory wall. The term "infected necrosis" refers to bacterial invasion of necrotic pancreatic tissue.

Pancreatic abscess is often a late complication of acute necrotizing pancreatitis (ANP), occurring more than 4 weeks after the initial attack. The mortality rate associated with pancreatic abscess is generally less than that of infected necrosis. The mortality rate of pancreatitis may exceed 20% or more with infected pancreatic necrosis and is largely related to sepsis and multiorgan failure.

Next

Pathophysiology

A number of molecules mediating the inflammatory (NF-κB, cytokines/chemokines, adhesion molecules, and novel protein kinase C isoforms) and cell death responses (eg, caspases) play a role in the pathogenesis of acute pancreatitis.

Pancreatitis begins in acinar cells and leads to the premature, intra-acinar activation of digestive zymogens into their active forms (eg, trypsinogen to trypsin); accumulation of large vacuoles in acinar cells; inflammation; and parenchymal cell death through apoptosis and necrosis.[2] The activated pancreatic enzymes cause autodigestion. These inflammatory processes lead to collection of fluid in and around the pancreas. In addition injury to the pancreatic duct or its branches lead to leakage of pancreatic enzymes into the lesser sac and the retroperitoneum. The enzyme rich fluid and necrotic collections if persistent will eventually develop fibrosis around its periphery leading to pseudocysts and WOPN. These processes often follow severe acute pancreatitis(SAP) as opposed to mild acute pancreatitis.

Acute necrotic pancreatitis is the most severe end of a spectrum of inflammation associated with pancreatitis. Inflammation in this situation has caused cell death. The resultant devitalized tissue becomes a potential bed for infection. The amount of necrotic tissue is the strongest predictor of mortality necrotic pancreatitis. After necrotic pancreatitis three potential outcomes exist: resolution, persistent fluid collection (pseudocyst)/necrosis (WOPN), or formation of abscess or infected necrosis.

Pseudocysts and abscesses can be single or multiple and vary greatly in size and location. Approximately 3% of patients with acute pancreatitis develop pancreatic abscess.

Previous
Next

Epidemiology

United States

The incidence of pancreatitis is approximately 185,000 cases per year. At least 80% of cases are due to alcohol and cholelithiasis. ANP is reported by some to occur in approximately 20% of all episodes of pancreatitis. Although sterile necrosis may occur, a variable percentage develops infection of the necrotic tissue. Depending on the time course and the host's ability to encase the necrotic tissue, the lesion is either infected necrosis or an abscess.

Previous
Next

Prognosis

Risk assessment of acute pancreatitis (AP) depends upon clinical indices (eg, Ranson, Imrie, or Apache I/II Scores), the presence of extrapancreatic complications, an elevated C-reactive protein or hematocrit, an elevated procalcitonin, and the finding of pancreatic necrosis on CT scanning.

The prognosis may be worse in obese patients, after trauma, after organ transplantation, after coronary artery bypass surgery, or AP that is idiopathic.[3]

Morbidity/mortality

In the first 48-72 hours after the onset of acute pancreatitis using the Sepsis-Related Organ Failure Assessment (SOFA) score and contrast-enhanced CT scan (which has the highest diagnostic accuracy) one can predict future development of infected necrosis, multiorgan failure syndrome (MOFS) and death. Balthazar and Ranson's radiographic staging criteria predict the formation of pseudocysts and, therefore, abscesses. Note the following:

  • Grade A – Normal pancreas
  • Grade B - Focal or diffuse enlargement
  • Grade C - Mild peripancreatic inflammatory changes
  • Grade D - Single fluid collection
  • Grade E - Two or more fluid collections or gas within the pancreas or within peripancreatic inflammation. In grade A, B, C, or D, the probability of abscess formation is less than 2%. With grade E disease (2 or more collections of peripancreatic fluid), the probability rises to 57%.

Patients are at risk for sepsis and, ultimately, even death. The mortality rate approaches 100% if intervention and drainage are not undertaken for infected necrosis or abscess.

Pseudocysts and abscesses may result in prolonged abdominal pain, rupture leading to acute peritonitis, fistula formation, and erosion into vessels with acute hemorrhage. Pancreatic ascites or pleural effusion may result. Pseudocysts or abscesses may also cause hollow viscus obstruction by compression of surrounding structures, including the colon, stomach, duodenum, and the common bile duct.

Even with aggressive intravenous fluid replacement, nutritional support, and early intervention of pancreatic necrosis or abscess, the hospital mortality rate of SAP is about 20%.

Overall, the mortality rate from acute pancreatitis is low (< 1% for acute edematous pancreatitis), but it depends upon the proportion of patients in the group with severe pancreatitis complicated by MODS, with or without associated sepsis.

The presence of pancreatic necrosis is associated with an overall increase in mortality. The mortality rate from sterile pancreatic necrosis is 10% and rises to 30% with infection in the necrotic area.[4] One meta-analysis concluded that when organ failure and infected pancreatic necrosis are present together, it portends an even worse prognosis, with mortality reaching 43%.[5]

Complications

Complications include the following:

  • Fistula formation (eg, enterocutaneous following surgery, entero-entero, enterovascular)
  • Recurrent pancreatitis
  • Bowel obstruction
  • Death

Sex

Differences in sexual predilection are based on the difference in frequency of causative factors of the pancreatitis and include the following:

  • Women are more likely to have gallstone pancreatitis than men.
  • Men have alcohol-induced pancreatitis more commonly than women.
  • A difference in the rate of abscess formation between men and women has not been clearly demonstrated.
Previous
 
 
Contributor Information and Disclosures
Author

Abraham Mathew, MD, MS Professor of Medicine, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Hershey Medical Center, Pennsylvania State University College of Medicine

Abraham Mathew, MD, MS is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Received ownership interest from Hershey Endoscopy Center for partner of ambulatory surgery center, practice site; Received consulting fee from Boston Scientific for consulting.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Douglas M Heuman, MD, FACP, FACG, AGAF Chief of Hepatology, Hunter Holmes McGuire Department of Veterans Affairs Medical Center; Professor, Department of Internal Medicine, Division of Gastroenterology, Virginia Commonwealth University School of Medicine

Douglas M Heuman, MD, FACP, FACG, AGAF is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Physicians, American Gastroenterological Association

Disclosure: Received grant/research funds from Novartis for other; Received grant/research funds from Bayer for other; Received grant/research funds from Otsuka for none; Received grant/research funds from Bristol Myers Squibb for other; Received none from Scynexis for none; Received grant/research funds from Salix for other; Received grant/research funds from MannKind for other.

Chief Editor

BS Anand, MD Professor, Department of Internal Medicine, Division of Gastroenterology, Baylor College of Medicine

BS Anand, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American College of Gastroenterology, American Gastroenterological Association, American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Additional Contributors

Jose A Perez, Jr, MD, MBA, MSEd Residency Director, Internal Medicine Residency Program, Vice Chair of Education, Department of Medicine, Methodist Hospital; Associate Professor of Clinical Medicine, Weill Cornell Medical College

Jose A Perez, Jr, MD, MBA, MSEd is a member of the following medical societies: American Association for Physician Leadership, American College of Physicians, Society of General Internal Medicine, Society of Hospital Medicine

Disclosure: Nothing to disclose.

Acknowledgements

Eric R Frizzell, MD

Instructor of Medicine, Uniformed Services University of the Health Sciences; Consulting Staff, Department of Medicine, Division of Gastroenterology, Walter Reed Army Medical Center

Eric R Frizzell, MD is a member of the following medical societies: American College of Gastroenterology, American College of Physicians, American Gastroenterological Association, and American Society for Gastrointestinal Endoscopy

Disclosure: Nothing to disclose.

Alan BR Thomson, MD Professor of Medicine, Division of Gastroenterology, University of Alberta, Canada

Alan BR Thomson, MD is a member of the following medical societies: Alberta Medical Association, American College of Gastroenterology, American Gastroenterological Association, Canadian Association of Gastroenterology, Canadian Medical Association, College of Physicians and Surgeons of Alberta, and Royal College of Physicians and Surgeons of Canada

Disclosure: Nothing to disclose.

References
  1. Banks PA, Bollen TL, Dervenis C, et al. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013 Jan. 62(1):102-11. [Medline].

  2. Gukovsky I, Pandol SJ, Mareninova OA, Shalbueva N, Jia W, Gukovskaya AS. Impaired autophagy and organellar dysfunction in pancreatitis. J Gastroenterol Hepatol. 2012 Mar. 27 Suppl 2:27-32. [Medline]. [Full Text].

  3. Pitchumoni CS, Patel NM, Shah P. Factors influencing mortality in acute pancreatitis: can we alter them?. J Clin Gastroenterol. 2005 Oct. 39(9):798-814. [Medline].

  4. Dugernier T, Dewaele J, Laterre PF. Current surgical management of acute pancreatitis. Acta Chir Belg. 2006 Mar-Apr. 106(2):165-71. [Medline].

  5. Petrov MS, Shanbhag S, Chakraborty M, Phillips AR, Windsor JA. Organ failure and infection of pancreatic necrosis as determinants of mortality in patients with acute pancreatitis. Gastroenterology. 2010 Sep. 139(3):813-20. [Medline].

  6. Seewald S, Ang TL, Richter H, Teng KY, Zhong Y, Groth S, et al. Long-term results after endoscopic drainage and necrosectomy of symptomatic pancreatic fluid collections. Dig Endosc. 2012 Jan. 24(1):36-41. [Medline].

  7. Tenner S, Baillie J, DeWitt J, Vege SS. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013 Sep. 108(9):1400-15; 1416. [Medline].

  8. Ciesek S, Manns MP, Kruger M. [Retroperitoneal abscess in a man with severe necrotizing pancreatitis]. Dtsch Med Wochenschr. 2006 Sep 8. 131(36):1937-40. [Medline].

  9. Mathew A, Biswas A, Meitz KP. Endoscopic necrosectomy as primary treatment for infected peripancreatic fluid collections (with video). Gastrointest Endosc. 2008 Oct. 68(4):776-82. [Medline].

  10. Loveday BP, Mittal A, Phillips A, Windsor JA. Minimally invasive management of pancreatic abscess, pseudocyst, and necrosis: a systematic review of current guidelines. World J Surg. 2008 Nov. 32(11):2383-94. [Medline].

  11. Bucher P, Pugin F, Morel P. Minimally invasive necrosectomy for infected necrotizing pancreatitis. Pancreas. 2008 Mar. 36(2):113-9. [Medline].

  12. Papachristou GI, Takahashi N, Chahal P, Sarr MG, Baron TH. Peroral endoscopic drainage/debridement of walled-off pancreatic necrosis. Ann Surg. 2007 Jun. 245(6):943-51. [Medline].

  13. Chen J, Fukami N, Li Z. Endoscopic approach to pancreatic pseudocyst, abscess and necrosis: Review on recent progress. Dig Endosc. 2012 Sep. 24(5):299-308. [Medline].

  14. Loveday BP, Rossaak JI, Mittal A, Phillips A, Windsor JA. Survey of trends in minimally invasive intervention for necrotizing pancreatitis. ANZ J Surg. 2011 Jan. 81(1-2):56-64. [Medline].

  15. Bang JY, Wilcox CM, Trevino J, Ramesh J, Peter S, Hasan M, et al. Factors impacting treatment outcomes in the endoscopic management of walled-off pancreatic necrosis. J Gastroenterol Hepatol. 2013 Nov. 28(11):1725-32. [Medline]. [Full Text].

  16. Hookey LC, Debroux S, Delhaye M, Arvanitakis M, Le Moine O, Deviere J. Endoscopic drainage of pancreatic-fluid collections in 116 patients: a comparison of etiologies, drainage techniques, and outcomes. Gastrointest Endosc. 2006 Apr. 63(4):635-43. [Medline].

  17. Sikora SS, Khare R, Srikanth G, Kumar A, Saxena R, Kapoor VK. External pancreatic fistula as a sequel to management of acute severe necrotizing pancreatitis. Dig Surg. 2005. 22(6):446-51; discussion 452. [Medline].

  18. Will U, Wanzar C, Gerlach R, Meyer F. Interventional ultrasound-guided procedures in pancreatic pseudocysts, abscesses and infected necroses - treatment algorithm in a large single-center study. Ultraschall Med. 2011 Apr. 32(2):176-83. [Medline].

  19. Bakker OJ, van Santvoort HC, van Brunschot S, et al, for the Dutch Pancreatitis Study Group. Endoscopic transgastric vs surgical necrosectomy for infected necrotizing pancreatitis: a randomized trial. JAMA. 2012 Mar 14. 307(10):1053-61. [Medline].

 
Previous
Next
 
Contrast-enhanced CT scan of infected pancreatic pseudocyst.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.